Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V
FDA/DEA reschedules suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V, easing regulatory controls.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 10, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Manufacturers, distributors, and dispensers of suvorexant, lemborexant, and daridorexant. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date not specified in the excerpt; check the full Federal Register notice for the effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
These three drugs are moved from Schedule IV to Schedule V, reducing regulatory requirements (e.g., lower recordkeeping, less stringent security, and lower quota burdens).
Who it affects
Manufacturers, distributors, and dispensers of suvorexant, lemborexant, and daridorexant.
What you must do
Review and update internal controlled-substance procedures to reflect Schedule V status; adjust DEA registrations and quotas as needed.
Deadline
Effective date not specified in the excerpt; check the full Federal Register notice for the effective date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal - foxbusiness.com
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com